Clinical Trial Update: Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update for HS-10376 in advanced non-small cell lung cancer (NSCLC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• HS-10376

Snippet

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Conditions: Advanced Non-Small-Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN